Fibronectin產(chǎn)品信息
別稱：Fibronectin
物種：Human
屬性：Protein
標(biāo)記：Unconjugated
內(nèi)毒素（Endotoxin）
Less than 0.01 EU per μg by the LAL method.
無菌（Sterility）
Negative
支原體（Mycoplasma）
Negative.
純度（Purity）
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制劑（Formulation）
Supplied as 0.2 μm filtered solution in 12.5 mM Sodium citrate, pH6.2 with Sucrose as protectant.
Contact us for customized product form or formulation.
運(yùn)輸（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存儲(chǔ)（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 3 months under sterile conditions.
Fibronectin分子背景
Fibronectin (Fn) is a glycoprotein whose size ranges from 230 to 270 kDa and usually exists as a dimer, covalently linked by a pair of disulfide bonds at the C-termini. Each monomer consists of three repeating units: 12 Type I, 2 Type II, and 15–17 Type III domains which combined account for 90% of the FN sequence. The extracellular matrix (ECM) plays a key role as both structural scaffold and regulator of cell signal transduction in tissues. Fibronectin is one of the major ECM proteins in the trabecular meshwork (TM). It is found in the sheath material surrounding the elastin tendons that enter the TM from the ciliary muscle within the ciliary body. In times of ECM assembly and turnover, cells upregulate assembly of the ECM protein, FN. FN is assembled by cells into viscoelastic fibrils that can bind upward of 40 distinct growth factors and cytokines. These fibrils play a key role in assembling a provisional ECM during embryonic development and wound healing. Fibril assembly is also often upregulated during disease states, including cancer and fibrotic diseases.
關(guān)鍵字： Fibronectin;Fibronectin蛋白;Fibronectin重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。